Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.

Roxane DilcherStephan WallMattes GroßSabrina KatzdoblerOlivia WagemannCarla PalleisEndy WeidingerUrban FietzekAlexander BernhardtCarolin KurzChristian FerschmannMaximilian ScheifeleMirlind ZaganjoriJohannes GnörichKatharina BürgerDaniel JanowitzBoris-Stephan RauchmannSophia StöckleinPeter BartensteinVictor VillemagneJohn SeibylOsama SabriHenryk BarthelRobert PerneczkyFlorian SchöberlAndreas ZwergalGünter U HöglingerJohannes LevinNicolai FranzmeierMatthias Brendel

Published in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)

F-PI-2620 discriminates AD versus 4R tauopathies. Hypoperfusion serves as an additional neuronal injury biomarker in AD.

Keyphrases

cerebrospinal fluid
computed tomography
cognitive impairment
cognitive decline
positron emission tomography
pet ct
pet imaging
blood brain barrier
brain injury